Gastrointestinal Health

The primary endpoint of the study was clinical remission at week 52 with vedolizumab

Melatonin is linked to circadian rhythm, mitochondrial function, and neuroinflammation.

Individuals included in the study reported positive changes in fatigue, and disease activity displayed endoscopic and histologic remission.

Children with normal weight had different community relationships compared to children with overweight or obesity.

Repairing the intestinal epithelial barrier is paramount in the treatment of IBD.

Nearly 60% of patients who regained all the weight stayed in remission at 5 years post-surgery, according to study results.

The approval of irinotecan liposome offers an improved first-line treatment option for individuals diagnosed with metastatic pancreatic adenocarcinoma.

Researchers will continue to research how lantibiotic’s antimicrobial effects can be harnessed for good.

The designation offers support in developing potential new medicines, treatment, and diagnosis to prevent rare conditions, like EoE.

Radioligands may be able to deliver radiation to advanced tumor cells anywhere in the body.

Jennifer Marsh, PharmD, BCCCP, discusses the current standard of care for hepatic encephalopathy, highlighting challenges in treatment, prescription drug coverage, transition of care, and outpatient treatment access.

There may be a pathophysiological basis for therapy relating to the to the gut-liver axis.

Findings from a recent murine model may translate to the human gut microbiome, but assessing chlorine’s effects on the gut microbiome remains complex.

Despite the insignificant differences in efficacy, biomarkers, therapeutic drug level, and ADAs, patients reported a significant number of nocebo effects.

Iberzaplstat was non-inferior to standard of care vancomycin, was safe and tolerable, and will advance into a phase 3 trial.

No significant demographic or phenotypic differences were found between HLA-DQA1*05 carriers versus non-carriers, in either treatment group.

The approval marks the first major innovation in the United States for the treatment of erosive GERD in over 30 years.

Etrasimod is an advanced synthetic compound classified as a selective modulator of Sphingosine 1-phosphate (S1P) receptors, specifically targeting S1P1, S1P4, and S1P5 receptors .

In a clinical trial, 2 vonoprazan-based regimens demonstrated higher rates of eradication as well as low rates of adverse effects compared to lansoprazole triple therapy.

Mirikizumab-mrkz (Omvoh; Eli Lilly and Company) is the first IL-23p19 antagonist approved for adult patients with moderately to severely active ulcerative colitis.

Infliximab-dyyb (Zymfentra; Celltrion USA) is a subcutaneous treatment for the maintenance treatment of adults with moderately to severely active ulcerative colitis and Crohn disease.

Additional research is needed to further evaluate whether adequate emotional support is linked to improvements in health-related quality of life in adults diagnosed with other cancer.

New innovations are revolutionizing diagnostics and optimizing treatment outcomes, marking significant strides in the fight against digestive diseases.